• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Biochemical Markers of Bone Fragility in Patients with Diabetes. A Narrative Review by the IOF and the ECTS.糖尿病患者骨脆性的生化标志物。国际骨质疏松基金会（IOF）和欧洲钙化组织协会（ECTS）的叙述性综述
J Clin Endocrinol Metab. 2023 May 8;108(10):e923-36. doi: 10.1210/clinem/dgad255.
2
Biochemical Markers of Bone Fragility in Patients With Diabetes.糖尿病患者骨脆性的生化标志物
J Clin Endocrinol Metab. 2023 May 8. doi: 10.1210/clinem/dgad255.
3
Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF.绝经前女性骨质疏松症：欧洲钙化组织学会（ECTS）和国际骨质疏松基金会（IOF）的临床叙述性综述
J Clin Endocrinol Metab. 2020 Aug 1;105(8). doi: 10.1210/clinem/dgaa306.
4
Bariatric surgery and skeletal health: A narrative review and position statement for management by the European Calcified Tissue Society (ECTS).减重手术与骨骼健康：欧洲钙化组织协会（ECTS）的管理叙述性综述和立场声明。
Bone. 2022 Jan;154:116236. doi: 10.1016/j.bone.2021.116236. Epub 2021 Oct 22.
5
Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.绝经后女性骨转换的生化标志物、内源性激素与骨折风险：OFELY研究
J Bone Miner Res. 2000 Aug;15(8):1526-36. doi: 10.1359/jbmr.2000.15.8.1526.
6
Advanced glycation end products are not associated with bone mineral density, trabecular bone score, and bone turnover markers in adults with and without type 1 diabetes: a cross-sectional study.晚期糖基化终产物与1型糖尿病成人患者及非1型糖尿病成人患者的骨密度、骨小梁评分和骨转换标志物无关：一项横断面研究。
JBMR Plus. 2024 Jan 4;8(3):ziad018. doi: 10.1093/jbmrpl/ziad018. eCollection 2024 Feb.
7
Bone cells and bone turnover in diabetes mellitus.糖尿病中的骨细胞与骨转换
Curr Osteoporos Rep. 2015 Jun;13(3):186-91. doi: 10.1007/s11914-015-0265-0.
8
Prevalence and Risk Factors of Osteoporosis in Postmenopausal Women with Type 2 Diabetes Mellitus.2型糖尿病绝经后女性骨质疏松症的患病率及危险因素
Cent Eur J Public Health. 2017 Mar;25(1):3-10. doi: 10.21101/cejph.a4717.
9
Type 2 diabetes and bone fragility- An under-recognized association.2 型糖尿病与骨脆弱——一个被低估的关联。
Diabetes Metab Syndr. 2021 May-Jun;15(3):927-935. doi: 10.1016/j.dsx.2021.04.017. Epub 2021 Apr 24.
10
Sclerostin Regulation, Microarchitecture, and Advanced Glycation End-Products in the Bone of Elderly Women With Type 2 Diabetes.2型糖尿病老年女性骨骼中的硬化蛋白调节、微结构与晚期糖基化终产物
J Bone Miner Res. 2020 Dec;35(12):2415-2422. doi: 10.1002/jbmr.4153. Epub 2020 Oct 2.

引用本文的文献

1
Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus.2型糖尿病患者血清总硬化素水平及生物活性硬化素水平与骨代谢的关系
J Clin Transl Endocrinol. 2025 Apr 8;40:100393. doi: 10.1016/j.jcte.2025.100393. eCollection 2025 Jun.
2
Combined Romosozumab and Raloxifene treatment targets impaired bone quality in a male murine model of diabetic kidney disease.在糖尿病肾病雄性小鼠模型中，联合使用罗莫单抗和雷洛昔芬治疗可针对受损的骨质量。
Bone. 2025 May;194:117415. doi: 10.1016/j.bone.2025.117415. Epub 2025 Jan 28.
3
A trend of osteocalcin in diabetes mellitus research: bibliometric and visualization analysis.糖尿病研究中骨钙素的趋势：文献计量学与可视化分析
Front Endocrinol (Lausanne). 2025 Jan 13;15:1475214. doi: 10.3389/fendo.2024.1475214. eCollection 2024.
4
The effects of type 1 and type 2 diabetes mellitus on bone health in chronic kidney disease.1型和2型糖尿病对慢性肾脏病患者骨骼健康的影响。
Nat Rev Endocrinol. 2025 May;21(5):301-313. doi: 10.1038/s41574-024-01083-8. Epub 2025 Jan 16.
5
Effect of type 2 diabetes on biochemical markers of bone metabolism: a meta-analysis.2型糖尿病对骨代谢生化标志物的影响：一项荟萃分析。
Front Physiol. 2024 Jul 19;15:1330171. doi: 10.3389/fphys.2024.1330171. eCollection 2024.
6
Impact of Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone Mineral Density in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis.不同抗高血糖治疗方案对 2 型糖尿病患者骨转换标志物和骨密度的影响：系统评价和荟萃分析。
Int J Mol Sci. 2024 Jul 22;25(14):7988. doi: 10.3390/ijms25147988.
7
Ethnic Variations in the Levels of Bone Biomarkers (Osteoprostegerin, Receptor Activator of Nuclear Factor Kappa-Β Ligand and Glycoprotein Non-Metastatic Melanoma Protein B) in People with Type 2 Diabetes.2型糖尿病患者骨生物标志物（骨保护素、核因子κB受体活化因子配体和糖蛋白非转移性黑色素瘤蛋白B）水平的种族差异
Biomedicines. 2024 May 6;12(5):1019. doi: 10.3390/biomedicines12051019.
8
The Use of Bone-Turnover Markers in Asia-Pacific Populations.骨转换标志物在亚太人群中的应用。
Ann Lab Med. 2024 Mar 1;44(2):126-134. doi: 10.3343/alm.2023.0214. Epub 2023 Oct 23.
9
Advanced glycation and glycoxidation end products in bone.骨中的糖基化终末产物和糖基氧化终末产物。
Bone. 2023 Nov;176:116880. doi: 10.1016/j.bone.2023.116880. Epub 2023 Aug 12.

本文引用的文献

1
Bone Turnover Markers: Basic Biology to Clinical Applications.骨转换标志物：基础生物学与临床应用。
Endocr Rev. 2023 May 8;44(3):417-473. doi: 10.1210/endrev/bnac031.
2
Impact of treatment with active vitamin D calcitriol on bone turnover markers in people with type 2 diabetes and stage 3 chronic kidney disease.活性维生素 D 骨化三醇治疗对 2 型糖尿病和 3 期慢性肾脏病患者骨转换标志物的影响。
Bone. 2023 Jan;166:116581. doi: 10.1016/j.bone.2022.116581. Epub 2022 Oct 8.
3
Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk.糖尿病与抗吸收治疗对骨折风险的获益。
J Bone Miner Res. 2022 Nov;37(11):2121-2131. doi: 10.1002/jbmr.4697. Epub 2022 Oct 7.
4
Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes.老年 1 型糖尿病患者骨转换的生化标志物。
J Clin Endocrinol Metab. 2022 May 17;107(6):e2405-e2416. doi: 10.1210/clinem/dgac099.
5
Bone fragility in diabetes: novel concepts and clinical implications.糖尿病中的骨脆性：新概念与临床意义
Lancet Diabetes Endocrinol. 2022 Mar;10(3):207-220. doi: 10.1016/S2213-8587(21)00347-8. Epub 2022 Jan 31.
6
Bone Microarchitecture and Strength in Long-Standing Type 1 Diabetes.长期 1 型糖尿病患者的骨微结构和骨强度。
J Bone Miner Res. 2022 May;37(5):837-847. doi: 10.1002/jbmr.4517. Epub 2022 Mar 8.
7
Hemoglobin A1c Threshold for Reduction in Bone Turnover in Men With Type 2 Diabetes Mellitus.血红蛋白 A1c 降低对 2 型糖尿病男性骨转换的影响。
Front Endocrinol (Lausanne). 2021 Dec 28;12:788107. doi: 10.3389/fendo.2021.788107. eCollection 2021.
8
Plasma FGF-21 and Sclerostin Levels, Glycemia, Adiposity, and Insulin Sensitivity in Normoglycemic Black and White Adults.正常血糖水平的黑人和白人成年人的血浆成纤维细胞生长因子21和硬化蛋白水平、血糖、肥胖及胰岛素敏感性
J Endocr Soc. 2021 Dec 1;6(1):bvab183. doi: 10.1210/jendso/bvab183. eCollection 2022 Jan 1.
9
Circulating Sclerostin Levels Are Positively Related to Coronary Artery Disease Severity and Related Risk Factors.循环骨硬化蛋白水平与冠状动脉疾病严重程度及相关危险因素呈正相关。
J Bone Miner Res. 2022 Feb;37(2):273-284. doi: 10.1002/jbmr.4467. Epub 2021 Dec 9.
10
Inflammation and sarcopenia: A focus on circulating inflammatory cytokines.炎症与肌肉减少症：关注循环炎症细胞因子。
Exp Gerontol. 2021 Oct 15;154:111544. doi: 10.1016/j.exger.2021.111544. Epub 2021 Sep 1.

糖尿病患者骨脆性的生化标志物。国际骨质疏松基金会（IOF）和欧洲钙化组织协会（ECTS）的叙述性综述

Biochemical Markers of Bone Fragility in Patients with Diabetes. A Narrative Review by the IOF and the ECTS.

作者信息

Meier Christian, Eastell Richard, Pierroz Dominique D, Lane Nancy E, Al-Daghri Nasser, Suzuki Atsushi, Napoli Nicola, Mithal Ambrish, Chakhtoura Marlene, El-Hajj Fuleihan Ghada, Ferrari Serge

机构信息

Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Switzerland.

Academic Unit of Bone Metabolism, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK.

出版信息

J Clin Endocrinol Metab. 2023 May 8;108(10):e923-36. doi: 10.1210/clinem/dgad255.

DOI:10.1210/clinem/dgad255
PMID:37155585
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10505554/
Abstract

CONTEXT

The risk of fragility fractures is increased in both type 1 and type 2 diabetes. Numerous biochemical markers reflecting bone and/or glucose metabolism have been evaluated in this context. This review summarizes current data on biochemical markers in relation to bone fragility and fracture risk in diabetes.

METHODS

Literature review by a group of experts from the International Osteoporosis Foundation (IOF) and European Calcified Tissue Society (ECTS) focusing on biochemical markers, diabetes, diabetes treatments and bone in adults.

RESULTS

Although bone resorption and bone formation markers are low and poorly predictive of fracture risk in diabetes, osteoporosis drugs seem to change bone turnover markers in diabetics similarly to non-diabetics, with similar reductions in fracture risk. Several other biochemical markers related to bone and glucose metabolism have been correlated with BMD and/or fracture risk in diabetes, including osteocyte-related markers such as sclerostin, HbA1c and advanced glycation end products (AGEs), inflammatory markers and adipokines, as well as IGF-1 and calciotropic hormones.

CONCLUSION

Several biochemical markers and hormonal levels related to bone and/or glucose metabolism have been associated with skeletal parameters in diabetes. Currently, only HbA1c levels seem to provide a reliable estimate of fracture risk, while bone turnover markers could be used to monitor the effects of anti-osteoporosis therapy.

摘要

背景

1型和2型糖尿病患者发生脆性骨折的风险均会增加。在此背景下，众多反映骨骼和/或糖代谢的生化标志物已得到评估。本综述总结了目前有关糖尿病患者中与骨脆性和骨折风险相关的生化标志物的数据。

方法

由国际骨质疏松症基金会（IOF）和欧洲钙化组织协会（ECTS）的一组专家进行文献综述，重点关注成人的生化标志物、糖尿病、糖尿病治疗及骨骼。

结果

尽管在糖尿病患者中，骨吸收和骨形成标志物水平较低且对骨折风险的预测性较差，但骨质疏松药物似乎对糖尿病患者骨转换标志物的改变与非糖尿病患者相似，骨折风险降低程度也相似。其他一些与骨和糖代谢相关的生化标志物已与糖尿病患者的骨密度（BMD）和/或骨折风险相关联，包括与骨细胞相关的标志物，如骨硬化蛋白、糖化血红蛋白（HbA1c）和晚期糖基化终末产物（AGEs）、炎症标志物和脂肪因子，以及胰岛素样生长因子-1（IGF-1）和钙调节激素。

结论

一些与骨和/或糖代谢相关的生化标志物及激素水平已与糖尿病患者的骨骼参数相关联。目前，似乎只有HbA1c水平能可靠地评估骨折风险，而骨转换标志物可用于监测抗骨质疏松治疗的效果。